*There are two major types of adipocytes in mammals*: white and brown. White adipocytes are specialized for the storage of excess energy \[[@r31]\]. In contrast, brown adipocytes dissipate chemical energy in the form of heat as a reaction against cold exposure or excess feeding \[[@r1], [@r4], [@r14], [@r20], [@r21], [@r38]\]. This thermogenic function of brown adipocytes results from the expression of a series of genes related to a high mitochondrial content and elevated cellular respiration that is largely uncoupled from ATP synthesis \[[@r35]\]. This uncoupling occurs through mitochondrial uncoupling protein 1 (Ucp1), a mammalian brown adipocyte-specific protein that promotes proton leak across the inner mitochondrial membrane \[[@r4], [@r13]\].

There are at least 2 origins of Ucp1-positive adipocytes in mice: brown adipocytes consisting of the classical brown fat depots, which are located in the interscapular region, and beige adipocytes residing in white fat depots. Both cell types up-regulate Ucp1 expression in response to β adrenergic receptor activation \[[@r3], [@r28], [@r37], [@r46]\]. However, beige adipocytes resemble white adipocytes in having extremely low basal expression of *Ucp1*, whereas classical brown adipocytes constitutively express *Ucp1* \[[@r46]\]. In accordance with the differential regulation of *Ucp1* expression, a distinct commitment/differentiation process is suggested between classical brown adipocytes and beige adipocytes in mice; classical brown adipocytes are derived from Myf-5-positive myoblast precursors, whereas beige adipocytes arise from non-Myf-5 lineage cells \[[@r36]\]. Certain studies have explored the cell origin of beige adipocytes and showed a direct conversion from white adipocytes \[[@r16]\], differentiation from beige preadipocytes located in white fat depots \[[@r46]\], commitment/differentiation of Sca1^+^/CD45^−^/Mac1^−^ stem cells \[[@r33]\] and commitment/differentiation from Pdgfrα^+^/CD34^+^/Sca1^+^ stellate-like cells, which can be bipotentially differentiated into white adipocytes and beige adipocytes \[[@r18]\]. Thus, beige adipocytes may be induced from multiple types of cells.

Recent findings that adult humans have functional brown adipocytes \[[@r6], [@r26], [@r32], [@r43], [@r45]\] have triggered a focus on brown adipocyte activation as a novel therapeutic treatment for obesity \[[@r5]\]. In fact, the activation of human brown adipocytes is responsible for energy expenditure during acute cold exposure \[[@r29]\]. Comprehensive profiles of gene expression indicate a similar pattern between human brown adipocytes and mouse beige adipocytes but not mouse classical brown adipocytes, suggesting that human brown adipocytes have compatible characteristics to mouse beige adipocytes \[[@r37], [@r46]\]. In mice, increases in the number of beige adipocytes in the white fat depots are associated with protection against diet-induced obesity and metabolic dysfunction, including insulin resistance in mice \[[@r34], [@r44]\]. Therefore, clarification of the factors affecting the development of beige adipocytes is a prerequisite to basic information on beige adipocyte-mediated regulation of energy metabolism. The present study explores the conditions to induce beige adipocytes without exogenous gene transfer in 3T3-L1 white preadipocytes.

MATERIALS AND METHODS {#s1}
=====================

*Materials*: The following reagents were purchased from Sigma (St. Louis, MO, U.S.A.): dexamethasone (Dex), 3-isobutyl-1-methylxanthine (IBMX), insulin (Ins), triiodothyronine (T~3~), rosiglitazone (Rosi) and isoproterenol (Iso).

*Cell culture*: The 3T3-L1 preadipocytes were cultured as described previously \[[@r40]\]. The standard protocol of differentiation in 3T3-L1 cells \[[@r39]\] was treated as the control: two days after reaching confluence (day 0), the cells were cultured in DMEM with 10% FBS and antibiotics (growth medium) in the presence of differentiation inducers (Dex (0.25 *µ*M), IBMX (0.5 mM) and Ins (10 *µ*g/m*l*)) for 2 days, followed by culture in growth medium supplemented with Ins (5 *µ*g/m*l*). According to the protocol, 3T3-L1 cells are differentiated to white adipocytes on day 8 \[[@r41]\]. In addition to the control protocol, Rosi (1 *µ*M), T~3~ (50 nM) and IBMX (0.5 mM) treatments were used for the indicated period. On day 8, lipid accumulation was examined using oil red O staining as described previously \[[@r40]\]. On day 8, the cells were further treated with or without Iso (10 *µ*M) for 4 hr.

The concentrations of the additional reagents used to induce the beige adipocytes were determined on the basis of the results from previous studies. Treatment with Rosi (1 *µ*M) for 5 to 7 days induced *Ucp1* expression in stromal vascular cells isolated from white fat depots \[[@r28], [@r30]\]. Treatment with T~3~ (50 nM) enhanced norepinephrine-induced *Ucp1* expression in primary brown adipocytes \[[@r22]\]. In addition, T~3~ is frequently used during brown adipocyte differentiation at concentrations of 1--250 nM \[[@r12], [@r15], [@r19], [@r28], [@r42]\].

*Real-time RT-quantitative PCR*: RNA isolation and real-time RT-quantitative PCR (qPCR) were performed as described previously \[[@r2], [@r11], [@r25]\]. The oligonucleotide primers for RT-qPCR are presented in [Table 1](#tbl_001){ref-type="table"}Table 1.Oligonucleotide PCR primers for RT-qPCROligonucleotideGenBank5′-primer3′-primeraccession number*aP2*5′-AAGGTGAAGAGCATCATAACCCT-3′5′-TCACGCCTTTCATAACACATTCC-3′NM_024406*C/ebpα*5′-CAAGAACAGCAACGAGTACCG-3′5′-GTCACTGGTCAACTCCAGCAC-3′NM_007678*C/ebpβ*5′-ACGACTTCCTCTCCGACCTCT-3′5′-CGAGGCTCACGTAACCGTAGT-3′NM_009883*Cidea*5′-AAACCATGACCGAAGTAGCC-3′5′-AGGCCAGTTGTGATGACTAAGAC-3′NM_007702*Cited1*5′-CGCTTCGTCCGTACCTCAGCT-3′5′-CAGCTGGGCCTGTTGGTCTC-3′NM_007709*Cox7a1*5′-AAAGTGCTGCACGTCCTTG-3′5′-TTCTCTGCCACACGGTTTTC-3′NM_009944*Ear2*5′-CAACCAGCCCTAAGTTCCAC-3′5′-TGAGGCAAGCATTAGGACAA-3′NM_007895*Pgc1α*5′-TGTGGAACTCTCTGGAACTGC-3′5′-GCCTTGAAAGGGTTATCTTGG-3′NM_008904*Pgc1β*5′-CTGACGGTGGAGCTTTGC-3′5′-AGGCTGGGAGCTGTGTCTT-3′NM_133249*Pparγ2*5′-TGCTGTTATGGGTGAAACTCTG-3′5′-CTGTGTCAACCATGGTAATTTCTT-3′NM_011146*Slc27a1*5′-GACAAGCTGGATCAGGCAAG-3′5′-GAGGCCACAGAGGCTGTTC-3′NM_011977*Tfam*5′-CAAAGGATGATTCGGCTCAG-3′5′-AAGCTGAATATATGCCTGCTTTTC-3′NM_009360*Tbp*5′-CCAATGACTCCTATGACCCCTA-3′5′-CAGCCAAGATTCACGGTAGAT-3′NM_013684*Ucp1*5′-ACTGCCACACCTCCAGTCATT-3′5′-CTTTGCCTCACTCAGGATTGG-3′NM_009463. The Ct value was determined, and the abundance of gene transcripts was analyzed using the ∆∆Ct method, using *TATA-binding protein*(*Tbp*) as the normalization gene \[[@r8]\].

*Statistical analyses*: The data are expressed as the mean ± SEM. The data on gene expression were log-transformed to provide an approximation of a normal distribution before analysis. The differences between the groups were examined by ANOVA. *P*\<0.05 was considered to be significant.

RESULTS {#s2}
=======

The 3T3-L1 preadipocytes were differentiated by treatments with Rosi and T~3~ in addition to the reagents used in the control protocol for differentiation to white adipocytes \[[@r39]\]. Oil red O staining on day 8 showed that the 3T3-L1 cells were efficiently differentiated to adipocytes, irrespective of the treatment ([Fig. 1A](#fig_001){ref-type="fig"}Fig. 1.Adipocyte differentiation in 3T3-L1 cells. 3T3-L1 cells were differentiated into adipocytes in the presence or absence of T~3~, IBMX and Rosi. (A) The lipid accumulation in cells without Iso treatment on day 8 was examined using oil red O staining. (B) The gene transcript level of *aP2* in cells treated without Iso on day 8 was examined by RT-qPCR and expressed as ratios to *Tbp* levels with the level in the control 3T3-L1 cells (treatment A) set to 1. The data shown are the mean ± SE (n=6).). Expression of *aP2*, a fatty-acid binding protein expressed in adipocytes, was comparable among groups, which was verified by RT-qPCR analyses ([Fig. 1B](#fig_001){ref-type="fig"}) \[[@r47]\].

We also examined expression level of transcription factors related to adipogenesis \[[@r41]\]. The expression level of *Pparγ2* in treatments D and E was significantly lower than that in treatment B ([Fig. 2A](#fig_002){ref-type="fig"}Fig. 2.The expression of adipogenic transcription factors in 3T3-L1 cells. 3T3-L1 cells were differentiated into adipocytes in the presence or absence of T~3~, IBMX and Rosi. The gene transcript levels of *Pparγ2*(A), *C/ebpα* (B) and *C/ebpβ* (C) in cells treated without Iso on day 8 were examined by RT-qPCR and expressed as ratios to *Tbp* levels with the level in the control 3T3-L1 cells (treatment A) set to 1. The data shown are the mean ± SE (n=6). ^a,b,c^Means that do not have a common letter above the bars differ significantly (*P*\<0.05).). Compared to the control treatment A, the gene transcript levels of *C/ebpα* were lower in treatments B, C and E ([Fig. 2B](#fig_002){ref-type="fig"}). The expression level of *C/ebpβ* was comparable among treatments ([Fig. 2C](#fig_002){ref-type="fig"}).

*Ucp1* expression is restricted in brown/beige adipocytes in mammals \[[@r4], [@r13]\]. The expression of *Ucp1* was not reproducibly detected in any cells without β adrenergic activation (data not shown). In contrast, significant *Ucp1* expression was detected in all the cells treated with Iso ([Fig. 3](#fig_003){ref-type="fig"}Fig. 3.The expression of *Ucp1* in 3T3-L1 cells. 3T3-L1 cells were differentiated into adipocytes in the presence or absence of the indicated factors. On day 8, the cells were further treated with Iso for 4 hr. *Ucp1* expression was examined by RT-qPCR and expressed as ratios to *Tbp* levels with the level in the control 3T3-L1 cells (treatment A) set to 1. The data shown are the mean ± SE (n=6). ^a,b,c^Means that do not have a common letter above the bars differ significantly (*P*\<0.05).). Treatment with the mixture of T~3~, IBMX and Rosi (treatment E) enhanced Iso-induced *Ucp1* expression; the expression level of *Ucp1* in treatment E was \~8-fold higher than that in the control treatment A (*P*=0.003). The prolonged IBMX treatment was essential for the increased expression of *Ucp1* in response to Iso treatment; the expression in treatment D, which lacked the IBMX used in treatment E, was not different from that in the control treatment A. *Ucp1* expression in treatment C, which is devoid of Rosi unlike treatment E, was still higher than that in the control treatment A (*P*=0.04), although the extent of the induction in treatment C was smaller than that in treatment E (*P*=0.03).

The expression of genes that are predominantly expressed in brown fat depots compared with white fat depots \[[@r35]\] was next examined ([Fig. 4](#fig_004){ref-type="fig"}Fig. 4.The expression of brown fat-selective genes in 3T3-L1 cells. 3T3-L1 cells were differentiated into adipocytes in the presence or absence of T~3~, IBMX and Rosi. On day 8, the expression of *Pgc1α* (A), *Pgc1β* (B), *Cidea*(C), *Cox7a1*(D) and *Tfam*(E) was examined by RT-qPCR and expressed as ratios to *Tbp* levels with the level in the control 3T3-L1 cells (treatment A) set to 1. The data shown are the mean ± SE (n=6). ^a,b^Means that do not have a common letter above the bars differ significantly (*P*\<0.05).). The expression levels of *Pgc1α*, *Pgc1β*, *Cox7a1* and *Tfam* were comparable among treatments, whereas the expression of *Cidea* was higher in the cells of treatments C (*P*=0.02) and E (*P*=0.04) than in treatment A.

Wu *et al.* \[[@r46]\] identified genes expressed selectively in beige adipocytes, but not brown adipocytes and white adipocytes, including *CD137*, *Slc27a1*, *Ear2*, *Tbx1* and *Tmem26*. Among these genes, significant expression of *CD137*, *Tbx1* and *Tmem26* was not detected in the 3T3-L1 cells, irrespective of the treatment (data not shown). The expression level of *Slc27a1* was not higher in treatments B-E than in treatment A ([Fig. 5A](#fig_005){ref-type="fig"}Fig. 5.The expression of beige adipocyte-selective genes in 3T3-L1 cells 3T3-L1 cells were differentiated into adipocytes in the presence or absence of T~3~, IBMX and Rosi. On day 8, the expression of *Slc27a1*(A), *Ear2*(B) and *Cited1*(C) was examined by RT-qPCR and expressed as ratios to *Tbp*, with the level in the control 3T3-L1 cells (treatment A) set to 1. The data shown are the mean ± SE (n=6). ^a,b,c^Means that do not have a common letter above the bars differ significantly (*P*\<0.05).); rather, it was significantly lower in treatments C (*P*=0.004), D (*P*=0.005) and E (*P*=0.001) than in the control treatment A. The expression level of *Ear2* was higher in treatment B (*P*=0.04) than in the control treatment A ([Fig. 5B](#fig_005){ref-type="fig"}). However, the expression was lower in treatments C (*P*=0.001) and D (*P*=0.03). Sharp *et al.* \[[@r37]\] independently identified the beige adipocyte-selective gene in cells following prolonged treatment with T~3~ and Rosi; they revealed *Cited1* as a novel beige adipocyte marker. The gene transcript level of *Cited1* in treatment D was significantly higher than that in the other treatments ([Fig. 5C](#fig_005){ref-type="fig"}).

DISCUSSION {#s3}
==========

The present results indicate that 3T3-L1 adipocytes treated with T~3~, Rosi and IBMX express higher *Ucp1* in response to β adrenergic activation. Basal expression of *Ucp1* in beige adipocytes is as low as that in white adipocytes, whereas *Ucp1* expression is enhanced in response to β adrenergic activation \[[@r46]\]. Significant expression of *Ucp1* was also detected in the control 3T3-L1 adipocytes (treatment A) when the cells were treated with Iso; the result is consistent with that by Mottillo and Grannerman \[[@r24]\]. Thus, the control 3T3-L1 adipocytes meet the definition of beige adipocytes by Wu *et al.* \[[@r46]\]. It is possible that the differences between white adipocytes and beige adipocytes are not discrete, but continuous. Our results suggest that 3T3-L1 cells chronically treated with the mixture of T~3~, Rosi and IBMX are closer to mature beige adipocytes.

T~3~, IBMX and Rosi are all needed for the efficient induction of *Ucp1* in response to β adrenergic receptor activation. However, whether T~3~ is essential is not known, because the observed Iso-induced *Ucp1* expression was not examined in cells treated with IBMX and Rosi, but without T~3~. In addition, the present results suggest that Rosi augments the effects of T~3~ and IBMX on the *Ucp1* induction in response to Iso treatment. The increase in *Ucp1* expression in white fat depots has been shown in mice chronically treated with Rosi \[[@r7], [@r28]\], implying a role of Rosi as an enhancer of beige adipocyte induction.

We focused on T~3~, Rosi and IBMX in view of the following evidence: prolonged treatment with Rosi with or without T~3~ in stromal vascular cells from white fat depots resulted in Iso-induced *Ucp1* induction \[[@r28], [@r30]\]. The overexpression of *C/ebpβ* enhanced cAMP-mediated *Ucp1* induction in 3T3-L1 cells \[[@r17]\]. Furthermore, IBMX is responsible for *C/ebpβ* induction during mitotic clonal expansion, i.e., days 0--2, in 3T3-L1 cells, which allows for the cells to differentiate to white adipocytes \[[@r47]\]; therefore, we expected up-regulation of the *C/ebpβ* expression in treatments C and E that were treated with the prolonged IBMX. However, the expression level of *C/ebpβ* was comparable among treatments A, C and E ([Fig. 2C](#fig_002){ref-type="fig"}), suggesting an activity of IBMX other than the regulation of *C/ebpβ* expression. There are nearly 100 cyclic nucleotide phosphodiesterases that catalyze cAMP or cGMP or both \[[@r10]\]. The non-selective phosphodiesterase inhibitor IBMX actually increased cytosolic concentration of cAMP in 3T3-L1 cells \[[@r9]\] and possibly increases cGMP concentration. It was recently revealed that cGMP-dependent protein kinase I in white adipocytes acts induces beige adipocytes \[[@r23]\] and may be involved in the IBMX-induced development of beige adipocytes.

Expression level of *C/ebpα* was lower in treatments B, C and E than in the control treatment A ([Fig. 2B](#fig_002){ref-type="fig"}); the transcript level of *C/ebpα* reflects adipocyte differentiation \[[@r41]\]. The precise reason for the decreased expression is unknown, although there are at least 2 possibilities: 1) the adipocyte differentiation was partially inhibited by treatments B, C and E, although lipid accumulation was unaffected; or 2) the decreased expression is partially related to the induction of beige (brown) adipocytes. The expression level of *C/ebpα* in beige (brown) adipocytes may be lower than that in white adipocytes. The results of the transcriptomic analyses (NCBI gene expression omnibus accession number: GSE8044), which were performed in the study by Seale *et al.* \[[@r35]\], indicated that the expression level of *C/ebpα* was lower in brown fat depots than in white fat depots.

Wu *et al.* \[[@r46]\] showed that the expression level of genes highly expressing in brown fat depots \[[@r35]\] was comparable between beige adipocytes and white adipocytes, although others observed higher expression of these genes in beige adipocytes \[[@r28], [@r30], [@r33]\]. Thus, the expression pattern of the brown fat-selective genes in 3T3-L1 cells treated with the mixture of T~3~, IBMX and Rosi essentially resembles that of the beige adipocytes identified by Wu *et al.* \[[@r46]\]. However, expression pattern of beige adipocyte-selective genes was different from the results by Wu *et al.* \[[@r46]\], suggesting that the characteristics of the beige-like adipocytes induced in this study are distinct from those developed by Wu *et al*. \[[@r46]\].

Our results also suggest the distinct cell context of the T~3~-, IBMX- and Rosi-induced beige-like adipocytes from those developed by Sharp *et al.* \[[@r37]\]. *Cited1* expression was increased by prolonged treatment with T~3~ and Rosi (treatment D: *P*=0.001) in the 3T3-L1 cells, which was similar to the results by Sharp *et al.* \[[@r37]\]. Thus, *Cited1* is likely to be induced by the activation of Pparγ, and the expression level of *Cited1* does not reflect the development of beige-like adipocytes, at least in the 3T3-L1 cell model. In addition, the T~3~- and Rosi-induced *Cited* expression is blocked by co-treatment with IBMX.

The present study clarifies the differentiation of 3T3-L1 white preadipocytes into beige-like adipocytes. As described above, beige adipocytes could be differentiated from white adipocytes \[[@r16]\], beige preadipocytes \[[@r46]\], Sca1^+^/CD45^−^/Mac1^−^ stem cells \[[@r33]\], pluripotent stem cells \[[@r27]\] and Pdgfrα^+^/SD34^+^/Sca1^+^ stellate-like cells \[[@r18]\]. Considering all the previous results with the present results, beige adipocytes could be developed from a variety of cells through their specific regulation. It was recently reported that a hematopoietin cocktail composed of stem cell factor, interleukin-6, fms-related tyrosine kinase 3 ligand and vascular endothelial growth factor efficiently differentiates human pluripotent stem cells to brown adipocytes \[[@r27]\]. Further studies are needed to pursue efficient beige adipocyte development, which would provide basic information on the differentiation of white preadipocytes to beige adipocytes.
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